News | July 01, 2007

Study Validates Savings Generated by MedSolutions’ Radiology Management Programs

July 2, 2007 - Believed to be the first study to demonstrate cost savings for radiology management with statistical analyses, a report by a Milliman team recently released by MedSolutions Inc. shows per member per month (PMPM) savings for a program that managed three high technology diagnostic imaging services covered by the MedSolutions: contract-computerized axial tomography (CAT), magnetic resonance imaging (MRI) and positron emission tomography (PET).

“The reductions compared to trend generated for the HMO after MedSolutions’ involvement are impressive, especially in light of double-digit inflation for high-tech imaging studies,” says Kathryn Fitch, RN, MEd and principal at Milliman. “We estimate that, compared to costs based on historical trends, the HMO’s allowed PMPM experience was lower during the MedSolutions management period by 30 percent during 2Q05-4Q05 and 42 percent during 1Q06-3Q06.”

Industry experts attribute about 10 percent of the total commercial medical spend to radiology, and the growth in volume has been significant. According to the Blue Cross Blue Shield Association (2006), over the course of three years (1999 to 2001) the number of MRI scans rose by more than 45 percent. Diagnostic imaging services paid under the Medicare Physician fee schedule grew more rapidly than any other physician category between 1999 and 2003, at 45 percent more than twice the growth for all physician services. The primary drivers of trends in imaging costs include increased inappropriate and redundant use of imaging, increased sales and installation of imaging scanners, development of new high-tech imaging and direct marketing to consumers.

For more information: www.medsolutions.com, www.milliman.com

Related Content

SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Novel PET Imaging Method Could Track and Guide Type 1 Diabetes Therapy
News | PET Imaging | August 03, 2018
Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...